KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Capital Expenditures (2018 - 2025)

Adaptive Biotechnologies' Capital Expenditures history spans 8 years, with the latest figure at $636000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 82.5% year-over-year to $636000.0; the TTM value through Dec 2025 reached $3.0 million, down 19.24%, while the annual FY2025 figure was $3.0 million, 19.24% down from the prior year.
  • Capital Expenditures for Q4 2025 was $636000.0 at Adaptive Biotechnologies, up from $409000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $45.4 million in Q3 2021 and bottomed at -$12.1 million in Q4 2022.
  • The 5-year median for Capital Expenditures is $2.3 million (2023), against an average of $3.5 million.
  • The largest annual shift saw Capital Expenditures soared 1127.75% in 2021 before it plummeted 230.75% in 2022.
  • A 5-year view of Capital Expenditures shows it stood at $9.2 million in 2021, then tumbled by 230.75% to -$12.1 million in 2022, then rose by 27.93% to -$8.7 million in 2023, then surged by 141.72% to $3.6 million in 2024, then plummeted by 82.5% to $636000.0 in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Capital Expenditures are $636000.0 (Q4 2025), $409000.0 (Q3 2025), and $655000.0 (Q2 2025).